Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

4th Year Sem II > Exam 4 PCAL > Flashcards

Exam 4 PCAL Flashcards

1
Q

Testosterone

A

Androgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Depo Testosterone

A

Androgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Androderm patch

A

Testosterone, Androgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Androgel

A

Testosterone, Androgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Testim

A

Testosterone, Androgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Jatenzo

A

Testosterone, Androgen
- oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Kyzatrex

A

Testosterone, Androgen
-oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tlando

A

Testosterone, Androgen
-oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Methyltestosterone

A

Androgen
- HRT for postmenopausal women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Danocrine

A

Androgen
- Use: endometriosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

fluoxymesterone

A

Halotestin,
Anabolic Steroids
- Use: erythropoiesis, bone disorder
- ADR: liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Halotestin

A

fluoxymesterone,
Anabolic Steroids
- Use: erythropoiesis, bone disorder
- ADR: liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

oxandrolone

A

Anavar,
Anabolic steroids
- Use: erythropoiesis, bone disorder
- ADR: liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Anavar

A

oxandrolone,
Anabolic steroids
- Use: erythropoiesis, bone disorder
- ADR: liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

oxymetholone

A

Anadrol,
Anabolic steroids
- Use: erythropoiesis, bone disorder
- ADR: liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Anadrol

A

oxymetholone,
Anabolic steroids
- Use: erythropoiesis, bone disorder
- ADR: liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

GnRH receptor antagonists

A

Androgen Deprivation Therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

GnRH receptor agonists

A

Androgen Deprivation Therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

5-alpha reductase inhibitors

A

Androgen Deprivation Therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Androgen receptor antagonists

A

Androgen Deprivation Therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

degarelix

A

Firmagon,
GnRH receptor antagonist
- Use: prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Firmagon

A

degarelix,
GnRH receptor antagonist
- Use: prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

elagolix

A

Orilissa,
GnRH receptor antagonist
- Use: endometriosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Orilissa

A

elagolix,
GnRH receptor antagonist
- Use: endometriosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

relugolix

A

Orgovyx,
GnRH receptor antagonist
- Use: prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Orgovyx

A

relugolix,
GnRH receptor antagonist
- Use: prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

leuprolide

A

Lupron,
GnRH receptor agonists
- long acting in
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Lupron

A

leuprolide,
GnRH receptor agonists
- long acting inj
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

nafarelin

A

Synarel,
GnRH receptor agonists
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Synarel

A

nafarelin,
GnRH receptor agonists
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

goserelin

A

Zoladex,
GnRH receptor agonists
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Zoladex

A

goserelin,
GnRH receptor agonists
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

buserelin

A

Suprefact,
GnRH receptor agonists
- nasal spray, inj
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Suprefact

A

buserelin,
GnRH receptor agonists
- nasal spray, inj
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

histrelin

A

Vantas,
GnRH receptor agonists
- SQ impant
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Vantas

A

histrelin,
GnRH receptor agonists
- SQ impant
- ADR: hot flashes (M/F)
- CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

triptorelin

A

GnRH receptor agonists
- ADR: hot flashes (M/F)
CONTRA: prego

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

finasteride

A

(Propecia, Proscar)- type 2 selective
5-alpha reductase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Propecia

A

finasteride, - type 2 selective
5-alpha reductase inhibitors
- Use: low dose > male patterned baldness
- ADR: Prego- male develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Proscar

A

finasteride, - type 2 selective
5-alpha reductase inhibitors
- Use: high dose > BPH
- ADR: Prego- male develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

dutasteride

A

Avodart, - non- selective
5-alpha reductase inhibitors
- ADR: Prego- male develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Avodart

A

dutasteride, - non- selective
5-alpha reductase inhibitors
- ADR: Prego- male develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

bicalutamide

A

Casodex,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Casodex

A

bicalutamide,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

apalutamide

A

Erleada,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Erleada

A

apalutamide,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

enzalutamide

A

Xtandi,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Xtandi

A

enzalutamide,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Nubeqa

A

darolutamide,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

darolutamide

A

Nubeqa,
Androgen receptor antagonists
- Use: prostate cancer
- Note: co-therapy w/ GnRH receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

clascoterone

A

Winlevi,
Androgen receptor antagonists
Use: acne (topical)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Winlevi

A

clascoterone,
Androgen receptor antagonists
Use: acne (topical)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

teplizumab

A

Tzield
- Use: early-stage T1D to delay disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Tzield

A

teplizumab
- Use: early-stage T1D to delay disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Afreeza

A

Ultra rapid-acting Insulin
- Use: inhaled- variable absorb
- ADR: bonchospams (REMS)
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Lispro

A

(Humalog, Admelog, Lyumjev)
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Humalog

A

Lispro,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Admelog

A

Lispro,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Lyumjev

A

Lispro,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

aspart

A

(Novolog, Fiasp)
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Novolog

A

Aspart,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Fiasp

A

Aspart,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

glulisine

A

Apidra,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Apidra

A

glulisine,
Rapid-acting Insulin
- Eat before meal
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Humulin R

A

Regular insulin, Short acting
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Novolin R

A

Regular insulin, Short acting
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Humulin N

A

NPH insulin,
Intermediate acting Insulin
- contain protamine, suspension
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Novolin N

A

NPH insulin,
Intermediate acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

detemir

A

Levemir,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Levemir

A

detemir,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

degludec

A

Tresiba,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Tresiba

A

degludec,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

glargine

A

(Lantus, Basaglar, Toujeo)
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Lantus

A

glargine,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Basaglar

A

glargine,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Toujeo

A

glargine,
Long-acting Insulin
U-300
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

glargine-yfgn

A

Semglee,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Semglee

A

glargine-yfgn,
Long-acting Insulin
- ADR: Wt gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

glucose

A

Treatment of hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

glucagon

A

(Baqsimi, Gvoke),
Treatment of hypoglycemia
- SQ or intranasal
- emergency use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Baqsimi

A

glucagon,
Treatment of hypoglycemia
- SQ or intranasal
- emergency use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Gvoke

A

glucagon,
Treatment of hypoglycemia
- SQ or intranasal
- emergency use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

dasiglucagon

A

Zegalogue,
Treatment of hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Zegalogue

A

dasiglucagon,
Treatment of hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

pramlintide

A

Symlin
- inj peptide amylin analog peptide
- co-admin w/ insulin, decr dose of insulin initially to prevent hypoglycemia
- Use: T1D, last stage T2D
- Effects:
1. decr glucagon secretion
2. decr gastric emptying rate
3. appetite suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Symlin

A

pramlintide
- inj amylin analog peptide
- co-admin w/ insulin, decr dose of insulin initially to prevent hypoglycemia
- Use: T1D, last stage T2D
- Effects:
1. decr glucagon secretion
2. decr gastric emptying rate
3. appetite suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

metformin

A

Glucophage
- Use: ONLY T2D
- MOA: incr insulin sensitivity >
incr glucose intake
- does NOT stimulate pancreas or incr endogenous insulin
- ADR: metallic taste, lactic acidosis
- NO hypoglycemia risk
- Excreted unchanged > need GOOD renal function
- STOP when iodinated contrast media scan bc kidney will stop elim med > 1. build-up, lactic acidosis
2. acute renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Glucophage

A

metformin
- Use: ONLY T2D
- MOA: incr insulin sensitivity >
incr glucose intake
- does NOT stimulate pancreas or incr endogenous insulin
- ADR: metallic taste, lactic acidosis
- NO hypoglycemia risk
- Excreted unchanged > need GOOD renal function
- STOP when iodinated contrast media scan bc kidney will stop elim med > 1. build-up, lactic acidosis
2. acute renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

rosiglitazone

A

Avandia,
Thiazolidinediones
- Use: T2D ONLY
ADR: anemia, edema (wt gain)
- CONTRA: HF, cardiovascular risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Avandia

A

rosiglitazone, Thiazolidinediones
- Use: T2D ONLY
ADR: anemia, edema (wt gain)
- CONTRA: HF, cardiovascular risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

pioglitazone

A

Actos,
Thiazolidinediones
- Use: T2D ONLY
- ADR: anemia, edema (wt gain)
- CONTRA: HF, cardiovascular risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Actos

A

pioglitazone,
Thiazolidinediones
- Use: T2D ONLY
ADR: anemia, edema (wt gain)
- CONTRA: HF, cardiovascular risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

acarbose

A

Precose,
Alpha-glucosidase inhibitors
Effect: slow breakdown/absorption of glucose, no effect on gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

Precose

A

acarbose,
Alpha-glucosidase inhibitors
Effect: slow breakdown/absorption of glucose, no effect on gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

miglitol

A

Glyset,
Alpha-glucosidase inhibitors
Effect: slow breakdown/absorption of glucose, no effect on gastric emptying

96
Q

Glyset

A

miglitol,
Alpha-glucosidase inhibitors
Effect: slow breakdown/absorption of glucose, no effect on gastric emptying

97
Q

dapagliflozin

A

Farxiga,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

98
Q

Farxiga

A

dapagliflozin,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

99
Q

canagliflozin

A

Invokana,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

100
Q

Invokana

A

canagliflozin,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

101
Q

Jardiance

A

empagliflozin,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

102
Q

empagliflozin

A

Jardiance,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

103
Q

Inpefa

A

sotagliflozin,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

104
Q

sotagliflozin

A

Inpefa,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

105
Q

bexagliflozin

A

Brenzavvy,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

106
Q

Brenzavvy

A

bexagliflozin,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

107
Q

ertugliflozin

A

Steglatro,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

108
Q

Steglatro

A

ertugliflozin,
SGLT2 inhibitors
- No stimulation of insulin > No hypoglycemia risk
- beneficial for HF and CKD
- ADR: polyuria, UTI

109
Q

Micronase

A

glyburide,
Sulfonylureas- Insulin Secretagogues
- AVOID in renal impairment bc ACTIVE metabolite

  • Long acting, given daily
  • MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
  • ADR: wt gain, hypoglycemia (less than insulin)
  • DDI: BB
  • CONTRA: prego
110
Q

glyburide

A

Micronase,
Sulfonylureas- Insulin Secretagogues
- AVOID in renal impairment bc ACTIVE metabolite

  • Long acting, given daily
  • MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
  • ADR: wt gain, hypoglycemia (less than insulin)
  • DDI: BB
  • CONTRA: prego
111
Q

glipizide

A

Glucotrol,
Sulfonylureas- Insulin Secretagogues
- PREFERRED in renal impairment bc INactive metabolite

  • Long acting, given daily
  • MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
  • ADR: wt gain, hypoglycemia (less than insulin)
  • DDI: BB
  • CONTRA: prego
112
Q

Glucotrol

A

glipizide,
Sulfonylureas- Insulin Secretagogues

  • PREFERRED in renal impairment bc INactive metabolite
  • Long acting, given daily
  • MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
  • ADR: wt gain, hypoglycemia (less than insulin)
  • DDI: BB
  • CONTRA: prego
113
Q

glimpepiride

A

Amaryl,
Sulfonylureas- Insulin Secretagogues
- Long acting, given daily
- MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
- ADR: wt gain, hypoglycemia (less than insulin)
- DDI: BB
- CONTRA: prego

114
Q

Amaryl

A

glimpepiride,
Sulfonylureas- Insulin Secretagogues
- Long acting, given daily
- MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
- ADR: wt gain, hypoglycemia (less than insulin)
- DDI: BB
- CONTRA: prego

115
Q

repaglinide

A

Prandin,
Meglitinides- Insulin Secretagogues
- short acting, given before meals
- MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
- ADR: wt gain, hypoglycemia (less than insulin)
- DDI: BB

116
Q

Prandin

A

repaglinide,
Meglitinides- Insulin Secretagogues
- short acting, given before meals
- MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
- ADR: wt gain, hypoglycemia (less than insulin)
- DDI: BB

117
Q

nateglinide

A

Starlix,
Meglitinides- Insulin Secretagogues
- short acting, given before meals
- MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
- ADR: wt gain, hypoglycemia (less than insulin)
- DDI: BB

118
Q

Starlix

A

nateglinide,
Meglitinides- Insulin Secretagogues
- short acting, given before meals
- MOA: close K+ channels (diff site than ATP binding site) > stimulate insulin release
- ADR: wt gain, hypoglycemia (less than insulin)
- DDI: BB

119
Q

exenatide

A

(Byetta, Bydureon),
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

120
Q

Byetta

A

exenatide,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

121
Q

Bydureon

A

exenatide,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

122
Q

liraglutide

A

(Victoza, Saxenda),
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

123
Q

Victoza

A

liraglutide,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

124
Q

Saxenda

A

liraglutide,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

125
Q

semaglutide

A

(Ozempic, Rybelsus),
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

126
Q

Ozempic

A

semaglutide,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

127
Q

Rybelsus

A

semaglutide,
GLP-1 receptor agonists- Insulin Secretagogues
ORAL
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

128
Q

dulaglutide

A

Trulicity,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

129
Q

Trulicity

A

dulaglutide,
GLP-1 receptor agonists- Insulin Secretagogues
ADR: N/V
CONTRA: prego
Low risk hypoglycemia

130
Q

tirzepatide

A

(Mounjaro, Zepbound)
GIP/GLP-1 receptor agonist- Insulin Secretagogues
- MOA: biased agonist
- ADR: pancreatitis (reversible), N/V
- Contra: prego

131
Q

Mounjaro

A

tirzepatide,
GIP/GLP-1 receptor agonist- Insulin Secretagogues
- MOA: biased agonist
- ADR: pancreatitis (reversible), N/V
- Contra: prego

132
Q

Zepbound

A

tirzepatide,
GIP/GLP-1 receptor agonist- Insulin Secretagogues
- MOA: biased agonist
- ADR: pancreatitis (reversible), N/V
- Contra: prego

133
Q

sitagliptin

A

Januvia,
DPP-IV inhibitors-Insulin Secretagogues

134
Q

Januvia

A

sitagliptin,
DPP-IV inhibitors-Insulin Secretagogues

135
Q

saxagliptin

A

Onglyza,
DPP-IV inhibitors-Insulin Secretagogues

136
Q

Onglyza

A

saxagliptin,
DPP-IV inhibitors-Insulin Secretagogues

137
Q

Tradjenta

A

linagliptin,
DPP-IV inhibitors-Insulin Secretagogues

138
Q

linagliptin

A

Tradjenta,
DPP-IV inhibitors-Insulin Secretagogues

139
Q

vidagliptin

A

Galvus,
DPP-IV inhibitors-Insulin Secretagogues

140
Q

Galvus

A

vidagliptin,
DPP-IV inhibitors-Insulin Secretagogues

141
Q

somatropins

A

human recombinant growth hormones,
to incr GH effects
- Use: GH deficiency, idiopathic short stature (ISS)
- Risk: malignancy bc incr cell growth
- CONTRA: leukemia or cancer

142
Q

somatrem

A

human recombinant growth hormones,
to incr GH effects
- Use: GH deficiency, idiopathic short stature (ISS)
- Risk: malignancy bc incr cell growth
- CONTRA: leukemia or cancer

143
Q

somatrogon

A

human recombinant growth hormones,
to incr GH effects
- Use: GH deficiency, idiopathic short stature (ISS)
- Risk: malignancy bc incr cell growth
- CONTRA: leukemia or cancer

144
Q

somapacitan

A

human recombinant growth hormones,
to incr GH effects
- Use: GH deficiency, idiopathic short stature (ISS)
- Risk: malignancy bc incr cell growth
- CONTRA: leukemia or cancer

145
Q

sermorelin

A

to incr GH effects
- MOA: mimic GHRH
- Use: test pituitary GH secretion

146
Q

tesamorelin

A

to incr GH effects
- MOA: mimic GHRH
- Use: test pituitary GH secretion

147
Q

recombinant human IGF-1

A

to incr GH effects
- Used when GH receptor is defective/ mutated
- Use: GH deficiency, Idiopathic short stature (ISS)

148
Q

octreotide

A

To decr GH effects,
Somatostatin Receptor Agonist
Use: gigantism (children), acromegaly (adults)
MOA: agonist at SST5 receptor > decr GH
ADR: abdomo pain, decr fat absorb, hyperglycemia

149
Q

lanreotide

A

To decr GH effects,
Somatostatin Receptor Agonist
Use: gigantism (children), acromegaly (adults)
MOA: agonist at SST5 receptor > decr GH
ADR: abdomo pain, decr fat absorb, hyperglycemia

150
Q

pasireotide

A

To decr GH effects,
Somatostatin Receptor Agonist
Use: gigantism (children), acromegaly (adults)
MOA: agonist at SST5 receptor > decr GH
ADR: abdomo pain, decr fat absorb, hyperglycemia

151
Q

bromocriptine

A

To decr GH effects,
D2 receptor agonist
Use: gigantism (children), acromegaly (adults), and breast cancer

152
Q

pegvisomant

A

Somavert, To decr GH effects,
GH receptor Antagonist

153
Q

Somavert

A

pegvisomant, To decr GH effects
GH receptor Antagonist

154
Q

Anti-resorptive drugs

A

Prevention and treatment of osteoporosis

155
Q

Anabolic drugs

A

Prevention and treatment of osteoporosis

156
Q

Estrogen

A

Anti-resorptive drugs
- short term
- Use: postmenopausal women
- decr bone osteoclast, incr cancer risk (breast, uterine)

157
Q

Fosamax

A

alendronate,
bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

158
Q

alendronate

A

Fosamax,
bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

158
Q

Raloxifene

A

Evista,
Anti-resorptive drugs,
- decr osteoclast and cancer risk (breast, uterine)
- ADR: hot flashes

159
Q

Evista

A

Raloxifene,
Anti-resorptive drugs

160
Q

risedronate

A

Actonel,
bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

161
Q

Actonel

A

risedronate,
bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

162
Q

ibandronate

A

Boniva,
bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

163
Q

Boniva

A

ibandronate,
bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

164
Q

zoledronate

A

bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

165
Q

pamidronate

A

bisphosphonates- Anti-resorptive drugs
- dose: once a week or daily
- Eat on an empty stomach w/ a full glass of water
- Eat daily Ca2+, but NOT at the same time as med
- stay upright 45-60min > prevents erosive esophagitis (could lead to esophageal cancer)
- ADR: muscle/ joint pain, osteonecrosis of the jaw (ONJ)
- Avoid: GERD, esophageal motility

166
Q

denosumab

A

Prolia,
Anti-resorptive drugs
- inj every few months
- MOA: bind to RANKL
- ADR: muscle/joint pain, lower back pain, incr inf risk, hypocalcemia

167
Q

Prolia

A

denosumab,
Anti-resorptive drugs
- inj every few months
- MOA: bind to RANKL
- ADR: muscle/joint pain, lower back pain, incr inf risk, hypocalcemia

168
Q

romosozumab

A

Evenity,
Anti-resorptive drugs
- Dual action: anti-resorptive and anabolic
- MOA: inhibits sclerostin > WNT signaling on > incr osteoblast
- ADR: muscle/ joint pain, incr cardio risk
- CONTRA: MI, stroke

169
Q

Evenity

A

romosozumab,
Anti-resorptive drugs
- Dual action: anti-resorptive and anabolic
- MOA: inhibits sclerostin > WNT signaling on > incr osteoblast
- ADR: muscle/ joint pain, incr cardio risk
- CONTRA: MI, stroke

170
Q

calcitonin

A

Anti-resorptive drugs
- Use: osteoporosis, minor analgesia
- Admin: nasal spray
- MOA: stop breaking down bone, stop reabsorption of Ca2+ > pee out
- Preferred over bisphosphonates: bedridden PT
ADR: fluid retention, salty tast, paresthesias

171
Q

Calcium

A

Anti-resorptive drugs

172
Q

Vitamin D

A

Anti-resorptive drugs

173
Q

teriparatide

A

Forteo,
Anabolic bone drugs
- Use: severe osteoporosis/osteopenia,
- rapidly incr BMD(max.2y) before switch to maintenance therapy
- Risk: osteosarcoma (bone cancer)
-ADR: hyperuricemia, orthostatic hypotension, hypocalcemia
- Caution: gout

174
Q

Forteo

A

teriparatide,
Anabolic bone drugs
- Use: severe osteoporosis/osteopenia,
- rapidly incr BMD(max.2y) before switch to maintenance therapy
- Risk: osteosarcoma (bone cancer)
-ADR: hyperuricemia, orthostatic hypotension, hypocalcemia
- Caution: gout

175
Q

abaloparatide

A

Tymlos,
Anabolic bone drugs
- Use: severe osteoporosis/osteopenia,
- rapidly incr BMD(max.2y) before switch to maintenance therapy
- Risk: osteosarcoma (bone cancer)
-ADR: hyperuricemia, orthostatic hypotension, hypocalcemia
- Caution: gout

176
Q

Tymlos

A

abaloparatide,
Anabolic bone drugs
- Use: severe osteoporosis/osteopenia,
- rapidly incr BMD(max.2y) before switch to maintenance therapy
- Risk: osteosarcoma (bone cancer)
-ADR: hyperuricemia, orthostatic hypotension, hypocalcemia
- Caution: gout

177
Q

cinacalcet

A

Sensipar,
Drugs affecting PTH function
- Use: 2ndary hyperparathyroidism

178
Q

Sensipar

A

cinacalcet,
Drugs affecting PTH function
- Use: 2ndary hyperparathyroidism

179
Q

etelcalcitide

A

Parsabiv,
Drugs affecting PTH function
- Use: 2ndary hyperparathyroidism

180
Q

Parsabiv

A

etelcalcitide,
Drugs affecting PTH function
-Use: 2ndary hyperparathyroidism

181
Q

Natpara

A

Drugs affecting PTH function
- Use: hypothyroidism

182
Q

palopegteriparatide

A

Yorvipath,
Drugs affecting PTH function
- Use: hypothyroidism

183
Q

Yorvipath

A

palopegteriparatide,
Drugs affecting PTH function
- Use: hypothyroidism

184
Q

Synthroid

A

T4: levothyroxine,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

185
Q

levothyroxine

A

T4: Synthroid, Levoxyl, Levothroid, Unithroid
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

185
Q

Levoxyl

A

T4: levothyroxine,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

186
Q

Unithroid

A

T4: levothyroxine,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

186
Q

Levothroid

A

T4: levothyroxine,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

187
Q

liothyronine

A

T3: Cytomel,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

188
Q

Cytomel

A

T3: Liothyronine,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

189
Q

Liotrix

A

T3 + T4: Thyrolar,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

190
Q

Thyrolar

A

T3 + T4: Liotrix,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

191
Q

Dessicated thyroid

A

Armour thyroid,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

192
Q

Armour thyroid

A

Dessicated thyroid,
Thyroid hormone preparations
- Use: treat hypothyroidism
- ADR: insomnia, cardiac stimulation
- eat on empty stomach, first thing in the morning
- avoid: milk, vit

193
Q

propylthiouracil (PTU)

A

Antithyroid drugs
- Use: hyperthyroidism
- 1-2 weeks to see effect
-ADR: skin, rash, joint pain, alopecia, hepatotoxicity, agranulocytosis

194
Q

methimazole

A

Tapazole,
Antithyroid drugs
- Use: hyperthyroidism
- 1-2 weeks to see effect
-ADR: skin, rash, joint pain, alopecia, hepatotoxicity, agranulocytosis

195
Q

Tapazole

A

methimazole,
Antithyroid drugs
- Use: hyperthyroidism
- 1-2 weeks to see effect
-ADR: skin, rash, joint pain, alopecia, hepatotoxicity, agranulocytosis

196
Q

iodide

A

Antithyroid drugs
- Use: thyroid storm

197
Q

131 I

A

Antithyroid drugs
- MOA: kill of thyroid gland

198
Q

cortisol = hydrocortisone

A

Glucocorticoids

199
Q

methylprednisolone

A

Medrol,
Glucocorticoids

199
Q

Prednisone

A

Deltasone,
Glucocorticoids

200
Q

Deltasone

A

Prednisone,
Glucocorticoids

201
Q

prednisolone

A

Glucocorticoids

202
Q

cortisone

A

Glucocorticoids

203
Q

Medrol

A

methylprednisolone,
Glucocorticoids

204
Q

triamcinolone

A

Glucocorticoids

205
Q

betamethasone

A

Glucocorticoids

206
Q

dexamethasone

A

Decadron,
Glucocorticoids

207
Q

Decadron

A

dexamethasone,
Glucocorticoids

208
Q

Vamorolone

A

Glucocorticoids

209
Q

fludrocortisone

A

Florinef,
Mineralocorticoid receptor agonist

210
Q

Florinef

A

fludrocortisone,
Mineralocorticoid receptor agonist

211
Q

Synthetic CRF

A

Achthrel
- Use: test for adrenal insufficiency

212
Q

Achthrel

A

synthetic CRF
- Use: test for adrenal insufficiency

213
Q

Synthetic ACTH

A

Cosyntropin
- Use: test for adrenal insufficiency

214
Q

Cosyntropin

A

Synthetic ACTH
- Use: test for adrenal insufficiency

215
Q

metyrapone

A

Cortisol synthesis inhibitors
- Use: Cushing’s disease
- MOA: inhibit CYP450

216
Q

ketoconazole

A

Cortisol synthesis inhibitors
-Use: Cushing’s disease
- MOA: inhibit CYP450

217
Q

osilodrostat

A

Cortisol synthesis inhibitors
- Use: Cushing’s disease

218
Q

calcipotriene

A

Dovonex,
Vitamin D analog
NON-retinoid
- Use: psoriasis
- ADR: skin irritation, hypercalcemia

219
Q

Dovonex

A

calcipotriene,
Vitamin D analog
NON-retinoid
- Use: psoriasis
- ADR: skin irritation, hypercalcemia

220
Q

tretinoin

A

Retin-A,
Retinoids
- Use: acne
- ADR: PHOTOLABILE- apply at night, dry skin, teratogenic
- DDI: peroxides

221
Q

Retin-A

A

tretinoin,
Retinoids
- Use: acne
- ADR: PHOTOLABILE- apply at night, dry skin, teratogenic
- DDI: peroxides

222
Q

isotretinoin

A

Accutane,
Retinoids
- Oral
- Use: severe acne
- ADR: severe teratogenicity, depression/suicide, dryness, desquamation, hyperlipidemia, hepatotoxicity ==> monitor

223
Q

Accutane

A

isotretinoin,
Retinoids
- Oral
- Use: severe acne
- ADR: severe teratogenicity, depression/suicide, dryness, desquamation, hyperlipidemia, hepatotoxicity ==> monitor

224
Q

adapalene

A

Differin,
Retinoids
- Use: acne
-ADR: photosensitivity (NOT photoliable), skin irritation, pregnancy risk

225
Q

Differin

A

adapalene,
Retinoids
- Use: acne
-ADR: photosensitivity (NOT photoliable), skin irritation, pregnancy risk

226
Q

acitretin

A

Soriatane,
Retinoids
- Oral
- Use: psoriasis
- ADR: prolonged teratogenicity (3 months)bc metabolized into etretinate, dry skin, mucous membrane irritation

226
Q

trifarotene

A

Aklief,
Retinoids

227
Q

Aklief

A

trifarotene,
Retinoids

228
Q

Soriatane

A

acitretin,
Retinoids
- Oral
- Use: psoriasis
- ADR: prolonged teratogenicity (3 months)bc metabolized into etretinate, dry skin, mucous membrane irritation

229
Q

tazarotene

A

Retinoids
- topical
- Use: psoriasis (no metabolite)

230
Q

alitretinoin

A

Retinoids
- Topical
- Use: korpsoi’s sarcoma- used in HIV PT
- MOA: non-selective agonist at RAR and RXR

231
Q

bexarotene

A

Retinoids
- oral, topical
- Use: cutaneous T-cell lymphoma
- MOA: selectively activates RXR receptors > induce apoptosis

232
Q

palovarotene

A

Retinoids
- Use: treat rare FOB (fibrodysplasia ossificans progressiva)

4th Year Sem II (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions